Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Income from Continuing Operations: 2019-2025

Historic Income from Continuing Operations for Keros Therapeutics (KROS) over the last 7 years, with Sep 2025 value amounting to -$7.3 million.

  • Keros Therapeutics' Income from Continuing Operations rose 86.25% to -$7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.4 million, marking a year-over-year increase of 134.32%. This contributed to the annual value of -$187.4 million for FY2024, which is 22.46% down from last year.
  • Latest data reveals that Keros Therapeutics reported Income from Continuing Operations of -$7.3 million as of Q3 2025, which was up 76.28% from -$30.7 million recorded in Q2 2025.
  • In the past 5 years, Keros Therapeutics' Income from Continuing Operations ranged from a high of $148.5 million in Q1 2025 and a low of -$53.0 million during Q3 2024.
  • Moreover, its 3-year median value for Income from Continuing Operations was -$43.1 million (2024), whereas its average is -$22.4 million.
  • In the last 5 years, Keros Therapeutics' Income from Continuing Operations tumbled by 328.21% in 2022 and then soared by 444.32% in 2025.
  • Over the past 5 years, Keros Therapeutics' Income from Continuing Operations (Quarterly) stood at -$6.9 million in 2021, then tumbled by 328.21% to -$29.7 million in 2022, then tumbled by 56.32% to -$46.5 million in 2023, then rose by 0.92% to -$46.0 million in 2024, then spiked by 86.25% to -$7.3 million in 2025.
  • Its Income from Continuing Operations stands at -$7.3 million for Q3 2025, versus -$30.7 million for Q2 2025 and $148.5 million for Q1 2025.